TY  - BOOK
ED  - National Institute for Clinical Excellence
TI  - Ritximab for aggressive non-Hodgkin's lymphoma
T2  - Technology appraisal 65
SN  - 1842573721
U1  - REFERENCE NAT 
PY  - 2003///
CY  - London
PB  - Nice
KW  - Pharmacology
KW  - Oncology
N1  - NON-HODGKIN'S
ER  -